Compare · AXGN vs OM
AXGN vs OM
Side-by-side comparison of Axogen Inc. (AXGN) and Outset Medical Inc. (OM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and OM operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.09B, about 27.3x OM ($76.7M).
- AXGN has been more active in the news (6 items in the past 4 weeks vs 2 for OM).
- OM has more recent analyst coverage (13 ratings vs 11 for AXGN).
- Company
- Axogen Inc.
- Outset Medical Inc.
- Price
- -
- -
- Market cap
- $2.09B
- $76.7M
- 1M return
- -23.49%
- -
- 1Y return
- +103.79%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 6
- 2
- Recent ratings
- 11
- 13
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Outset Medical Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Latest AXGN
- Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
- BofA Securities initiated coverage on AxoGen with a new price target
- Barclays initiated coverage on AxoGen with a new price target
- Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
- Axogen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
- SEC Form 424B5 filed by Axogen Inc.
- Amendment: Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Latest OM
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.
- SEC Form 4 filed by Outset Medical Inc.
- SEC Form 8-K filed by Outset Medical Inc.
- Chair and CEO Trigg Leslie sold $15,088 worth of shares (3,437 units at $4.39), decreasing direct ownership by 2% to 194,597 units (SEC Form 4) (tax withholding)
- General Counsel Brottem John L. sold $11,554 worth of shares (2,632 units at $4.39), decreasing direct ownership by 3% to 87,475 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Gaeta Renee sold $19,944 worth of shares (4,543 units at $4.39), decreasing direct ownership by 2% to 180,840 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by Outset Medical Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.
- SEC Form SCHEDULE 13G filed by Outset Medical Inc.
- SEC Form 10-Q filed by Outset Medical Inc.